Search results
Results from the WOW.Com Content Network
They have been marketed as herbal incense, or "herbal smoking blends", [6] and sold under common names such as K2, spice, [8] and synthetic marijuana. [5]
In the late 2000s, two of Huffman's cannabinoid compounds were found in street drugs K2 and Spice being sold in Germany as marijuana alternatives. "I figured once it got started in Germany it was going to spread. I'm concerned that it could hurt people," Huffman said. "I think this was something that was more or less inevitable.
Compared with classical cannabinoids, synthetic cannabinoids differ structurally. Some common synthetic cannabinoids are available in the market such as JWH-018, which is the most well-known naphthoylindole and JWH-250, a phenylacetylindole. They are sold under the brand name ”Spice” as a recreational drug over the past decade. [4]
Marketed under the names spice, spike, flamingo, or K2 — this underground drug has become one of the most inexpensive and dangerous ways to get high, reports say. Videos surfacing online have ...
A Florida defense lawyer was busted for allegedly smuggling legal documents soaked in the wild synthetic marijuana known as K2 into jail so inmates could get stoned, officials said.
JWH-018, a potent synthetic cannabinoid agonist discovered by John W. Huffman at Clemson University. It was often sold in legal smoke blends collectively known as "spice". Several countries and states have moved to ban it legally. JWH-073; CP-55940, produced in 1974, this synthetic cannabinoid receptor agonist is many times more potent than THC.
In 2021, MDMB-4en-PINACA was the most common synthetic cannabinoid identified by the Drug Enforcement Administration in the United States. [11] MDMB-4en-PINACA differs from 5F-MDMB-PINACA due to replacement of 5-fluoropentyl with a pent-4-ene moiety (4-en).
5F-CUMYL-PINACA (also known as SGT-25 and sometimes sold in e-cigarette form as C-Liquid) [1] is an indazole-3-carboxamide based synthetic cannabinoid. [2] 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB 1, having an EC 50 of <0.1 nM for human CB 1 receptors and 0.37 nM for human CB 2 receptors. [3]